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Abstract: There is increasing interest in the potential beneficial role of probiotic 
supplementation in the prevention and treatment of atopic diseases in children. Probiotics 
are defined as ingested live microorganisms that, when administered in an adequate 
amount, confer a health benefit to the host. They are mainly represented by Lactobacilli 
and Bifidobacteria. Several epidemiological data demonstrate that intestinal microflora of 
atopic children is different from the one of healthy children. Many literature data show that 
probiotics may modulate the intestinal microflora composition and may have 
immunomodulatory effect. Based on this hypothesis, probiotics are supposed to confer 
benefits to allergic diseases. Administration of probiotics when a natural population of 
indigenous intestinal bacteria is still developing could theoretically influence immune 
development by favoring the balance between Th1 and Th2 inflammatory responses. For 
this reason, some studies have evaluated the potential impact of probiotics supplementation 
in the prevention of atopic dermatitis, with contrasting results. Clinical improvement in 
immunoglobulin (Ig)E-sensitized (atopic) eczema following probiotic supplementation has 
been reported in some published studies and the therapeutic effects of probiotics on atopic 
dermatitis seemed to be encouraging. However, as far as the usefulness of probiotics as a 
prevention strategy is concerned, results are still inconclusive. In fact, the clinical benefits 
of probiotic therapy depend upon numerous factors, such as the type of bacteria, dosing 
regimen, delivery method and other underlying host factors, such as age and diet. More 
studies are still needed to definitively prove the role of probiotics in the treatment of 
allergic eczema. 
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1. Introduction 
In 1908, the Russian immunologist Elie Metchnikoff suggested that lactic acid bacteria in 
fermented milk may confer health benefits to humans [1] and paved the way for future research on the 
potential beneficial effects of probiotics. Since then, more than a century has passed and probiotics 
continue to capture the attention of the scientific community. The Food and Drug Organization of the 
United Nations (FAO) and World Health Organization (WHO) have defined probiotics as “live 
microorganisms which when administered in adequate amounts confer a health benefit to the host” [2]. 
A number of probiotics are currently commercially available; however, not all bacterial strains can be 
considered probiotics. Probiotics should in fact have some fundamental characteristics: they should be 
of human origin, non-pathogenic in nature and resistant to destruction by technical processing and by 
bile and gastric acids, they should be able to adhere to intestinal mucosa and colonize it, produce 
antimicrobial substances, modulate immune response and influence human metabolic activities [3]. 
The two most important bacterial genera with probiotic properties are Lactobacillus and 
Bifidobacterium [4]. Numerous studies evaluated the potential activities of probiotics in the prevention 
and treatment of human diseases, including allergic diseases and atopic dermatitis in particular. 
Atopic dermatitis (AD) is a common childhood-onset skin disease which, in nearly half of the 
cases, has an allergic origin. It is clinically characterized by a chronic or relapsing course, with periods 
of disease exacerbations alternating with various degrees of remission. The skin is dry and pruritus 
represents the hallmark symptom; it is disturbing and causes skin excoriations, substantially affecting 
the quality of life of patients and their relatives [5]. The precise etiology, pathophysiology, and 
pathogenesis of AD are not yet fully understood. Nevertheless, it can be considered the result of a 
complex interaction between genetic [6] and environmental factors, which are both implicated in the 
predisposition and development of disease [7]. The disease is associated with abnormalities in skin 
barrier molecules and in cells of the inflammatory response. The immunoregulatory abnormalities are 
characterized by impaired Th1-Th2 cytokines balance, with a prevalent activation of Th2 cytokines, 
which results in increased serum immunoglobulin IgE and elevated total circulating eosinophil count [8]. 
2. Hypothesized Probiotics Mechanisms of Action in Allergic Diseases 
As generally observed for other allergic diseases, incidence of AD has shown a twofold to threefold 
increase in the last decades, and currently it is estimated to be nearly 20% in the industrialized 
countries [9]. The first hypothesis proposed to explain the phenomenon of the increasing incidence of 
atopic diseases is the so-called “hygiene hypothesis” [10]. Immune response in neonates is dominated 
by Th2 cytokines, but, during the first year of life, immune responses shift to the Th1-based ones as a 
result of the repeated exposure to different infectious antigens [11]. The hygiene hypothesis is based 
on the finding that the prevalence of allergic diseases is inversely related to high-standard hygienic and 
sanitary conditions: smaller family sizes, less crowded accommodations, routine vaccinations and 
widespread use of antibiotics have all contributed to reduce childhood contact with pathogens, 
Pharmaceuticals 2012, 5 
 
729
decreasing the Th1-driven immune response and, on the contrary, favoring the persistence of the 
neonatal Th2-mediated one, which may later lead to appearance of allergic diseases [10]. 
More recently, another hypothesis has been proposed. The host’s primary microbial stimulation 
occurs with the establishment of the gut microflora, and exposure to commensal microflora or to 
specific bacterial strains may represent a key modulator of the immune system which may prevent 
development of atopic diseases [12,13]. At birth, the gastrointestinal tract of the newborn is sterile. 
After birth, neonatal microflora develops as a result of different intrinsic and extrinsic factors [14]. The 
developing microflora in the early postnatal period is involved in the activation of innate and adaptive 
immunity and the continuous microbial stimulus from the developing microflora is required for the 
successful maturation of the gut mucosal immune system. As a consequence, a lacking or inadequate 
microbial stimulus results in reduction of the intestinal surface area, alteration of mucosal enzyme 
patterns, mucosal barrier and mucosal IgA system [15,16], and abrogation of oral tolerance, that is the 
capacity of tolerating nonpathogenic antigens previously encountered on mucosal surfaces [17]. 
Unbalanced gut microflora favors the persistence of a neonatal Th2-oriented immune response, 
favoring development of atopy. 
It has been observed that gut microflora of atopic children is characterized by a reduced neonatal 
bifidobacteria to clostridia ratio, caused by augmented clostridia and reduced bifidobacteria 
colonization [18,19]. If unbalanced microflora may favor the development of atopic diseases, 
probiotics may be helpful because of their capacity of balancing the gut microecology, restoring the 
normal intestinal permeability, improving immunological gut barrier function and downregulating the 
production of pro-inflammatory cytokines. Moreover, it has been suggested that beneficial effects of 
probiotics against atopic diseases are associated with stimulation of Toll-like receptors (TLRs). 
Intestinal epithelial cells produce various pattern-recognition receptors that recognize microbial 
antigens, also called pathogen-associated molecular patterns (PAMPs). A class of these receptors are 
the TLRs. To date, 11 mammalian TLRs have been identified, whose expression pattern is cell type 
specific. Stimulation of TLRs by various PAMPs induces the differentiation of T cells, with Th1 cells 
that mediates cellular responses and inflammatory reactions and Th2 cells which mediates humoral 
responses, antiparasitic defense and allergic reactions [20]. Microflora-host interaction mediated by 
TLRs may play a role in the susceptibility to food allergy as hypothesized in the study by Bashir and 
colleagues [21] in which two groups of mice with a mutation or a deficiency of TLR-4, in contrast  
to TLR-4 wild type mice, showed a typical IgE-mediated immune response when exposed to  
allergic antigens. 
Given all the aforementioned evidences, numerous studies have evaluated the potential benefits of 
probiotics in children affected by allergic diseases, and in particular by AD, with contrasting results. 
We conducted a systematic review of the randomized controlled trials about the use of probiotics in 
prevention and treatment of pediatric atopic dermatitis (PAD), published in Pub-Med from 1997 to 
nowadays, in English language, using key words “probiotics”, “atopic dermatitis”. “children”, 
“prevention”, “treatment”. To our knowledge, this is the most up-to-date review on this topic. 
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3. Probiotics in the Prevention of Pediatric Atopic Dermatitis 
Numerous studies have evaluated the potential efficacy of probiotics in the prevention and 
treatment of allergic diseases in general, and of AD in particular, showing conflicting results. To date, 
17 trials of probiotics in the prevention of PAD have been published (Table 1). The majority of 
prevention studies performed from 2001 onwards focused on children at high risk for atopy, and in 
most of them, probiotics were administered 2–4 weeks prenatally to pregnant women and postnatally 
to infants for 6–12 months. The most frequently studied probiotic strain is Lactobacillus rhamnosus 
GG (LGG). Kalliomäki and colleagues [22] first evaluated efficacy of LGG in a double-blind 
randomized control trial (RCT) in a group of 132 infants at high risk for atopy. At the follow-up after 
two years, frequency of AD in infants supplemented with probiotics was half that of the placebo group 
(23% vs. 46%, respectively). The same research group subsequently evaluated the same cohort of 
infants four and seven years later confirming the persistence of a protective effect of probiotics against 
development of AD [23,24]. Preventive effects of LGG on AD were also demonstrated by  
Rautava et al. [25] in 2002, who evaluated its efficacy on 57 high-risk children breastfed by mothers 
supplemented with LGG strain. In the supplemented group the risk of developing atopic eczema was 
15%, while in the placebo group it was 47% [relative risk (RR): 0.32 (95% confidence interval (CI), 
0.12–0.85); p = 0.0098]. On the contrary, Kopp et al. [26] found no reduction of AD in high-risk 
infants supplemented with LGG. Supplementation with mixed probiotic strains was also evaluated. 
Kukkonen et al. [27] evaluated in a RCT the efficacy of supplementation with a mixture of 4 different 
probiotic bacterial strains in a large cohort of infants at high risk for atopy. At two years of age, 
probiotics did not reduce the cumulative incidence of all atopic diseases but significantly prevented 
both eczema and atopic eczema [Odds Ratio (OR) 0.74 (95% CI, 0.55–0.98); p = 0.035 for eczema; 
OR 0.66 (95% CI, 0.46–0.95); p = 0.025 for atopic eczema]. More recently, a trial by Dotterud et al. [28] 
studied a mixture of LGG, L. acidophilus La-5, Bifidobacterium animalis subsp. lactis administered 
prenatally to a population of non-selected mothers from the 36th week of gestation and postnatally to 
their exclusively breastfed infants for the first 3 months. They showed reduced cumulative incidence 
of AD after supplementation with mixed probiotics: in the intention-to-treat (ITT) analysis the OR was 
0.51 in infants supplemented with probiotics respect to placebo group (95% CI, 0.30–0.87; p = 0.013). 
In other three RCTs evaluating the efficacy of mixed probiotic strains, risk of sensitization and 
incidence of AD were reduced after probiotics supplementation [29–31]. On the contrary, no 
preventive effects of mixed probiotic strains on incidence of PAD were observed in other two  
RCTs [32,33]. A significant reduction of atopic eczema was demonstrated only in cesarean-delivered 
children supplemented with probiotics respect to placebo group (24.3% vs. 40.5%; OR, 0.47; 95% CI, 
0.23% to 0.96%; p = 0.035); whereas frequency of eczema (39.3% vs. 43.3%) and atopic eczema 
(24.0% vs. 25.1%) did not differ between groups [33]. A RCT published in 2008 [34] compared the 
efficacy of two different bacterial strains, L. rhamnosus and Bifidobacterium animalis subsp. lactis, in 
the prevention of pediatric eczema. At two years of age, only L. rhamnosus showed efficacy in 
reducing cumulative prevalence of eczema, whereas no effects were demonstrated for B. animalis. 
Supplementation during weaning with Lactobacillus F19 reduced cumulative incidence of atopic 
eczema in 179 infants in one trial [35]. On the contrary, two trials [36,37] with Lactobacillus acidophilus 
and L. reuteri ATCC, respectively, showed no preventive effects of probiotics on incidence of AD. At 
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six months, there was no difference in rates of AD between the supplemented group and the placebo 
group (25.8% vs. 22.7%, respectively; p = 0.629) in the first study [36]; in the second trial, cumulative 
incidence of atopic eczema was similar in the treated and untreated group (36% vs. 34%) [37]. Prenatal 
supplementation of pregnant women did not result in reduction of AD incidence in infants: incidence 
of AD and IgE-associated eczema in 1-yaer old infants at high risk for atopic diseases, born to 250 mothers 
supplemented with LGG from the 36th week of gestation to delivery, did not show a significant 
reduction respect to mothers who have not been supplemented [38]. Some recently published reviews 
and meta-analysis, including a Cochrane Collaboration review, concluded that there is still insufficient 
evidence for supporting the use of probiotics in the prevention of AD [39–42], whereas some others, 
including the most recently published one, stated that convincing evidence exists for encouraging 
supplementation with probiotics for the prevention of AD in children [43–46]. 
4. Probiotics in the Treatment of Pediatric Atopic Dermatitis 
In 1997, for the first time, a Finnish group of authors showed a significant improvement in atopic 
dermatitis children after a supplementation with probiotics. From then on, 19 trials regarding the 
treatment of PAD with probiotics have been published (Table 2) and even some meta-analysis and 
reviews, but current results and conclusions are not very convincing. 
The majority of studies investigated the effect of one probiotic strain vs. placebo in PAD. Majamaa 
and Isolauri [47] studied a group of infants with atopic eczema and a history of cow’s milk allergy. 
Patients were put on a cow’s milk elimination diet and randomized to receive extensively hydrolyzed 
whey formula with or without LGG. Moreover, in 11-breastfed atopic infants, LGG supplementation 
was given to nursing mothers. Results of this trial showed a significant improvement of SCORAD 
score after 1 month of supplementation only in the probiotic group. Three years later, the same group 
of Isolauri et al. [48] randomized 27 fully breastfed atopic infants to receive for 4 weeks an extensively 
hydrolyzed whey formula with LGG or Bifidobacterium lactis Bb-12 or placebo. An evaluation  
two months later demonstrated a significant improvement in SCORAD score in probiotic groups. The 
group of Kirjavainen performed 2 trials in 2002 [49] and 2003 [50] in which infants with early onset 
atopic eczema were randomized to receive in the first study a formula contained Bifidobacterium lactis 
Bb-12 vs. placebo, and in the second one a formula with viable or heat inactivated LGG vs. placebo. 
Results showed that probiotics supplementation modulates the composition of gut microbiota in a 
manner that may alleviate allergic inflammation and only viable probiotic strains are safe and 
potentially helpful for PAD treatment. In 2005 Weston et al. [51] recruited 53 children with  
moderate to severe AD to evaluate the effect of Lactobacillus fermentum. Results showed that an  
8-week supplementation was beneficial in improving extent and severity of AD. More recently  
Woo et al. [52] demonstrated that a 12-week supplementation of Lactobacillus Sakei in 75 children 
with atopic eczema-dermatitis syndrome was associated with a significant clinical improvement and a 
decrease of chemokine levels. 
On the contrary, other trials focused on a single strain supplementation, did not confirm the positive 
effects of probiotics in AD treatment. Brouwer et al. [53] randomized 50 infants with AD to receive 
Lactobacillus rhamnosus or Lactobacillus GG or placebo in a hydrolyzed whey formula for 3 months. 
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Table 1. Probiotics in the prevention of Atopic Dermatitis (AD) in children. 
Study Partecipants Probiotics Type of study Duration Outcome 
Kalliomäki et al. [22] 
132 high-risk 
infants for atopy 
Lactobacillus rhamnosus GG  
(1 × 1010 cfu daily) 
R, DB, PC 
From 2–4 weeks prenatally 
to 24 weeks postnatally  
At 2 years AD frequency halved in 
probiotic group vs. placebo (23% vs. 
46%) 
Kalliomäki et al. [23] 
107 high-risk 
infants for atopy 
Lactobacillus rhamnosus GG 
Same cohort of 
2001 
Same cohort of 2001 
4 years follow-up: protective effect 
against AD still detected in 
probiotic group 
Kalliomäki et al. [24] 
116 high-risk 
infants for atopy 
Lactobacillus rhamnosus GG 
Same cohort of 
2001 
Same cohort of 2001 
7 years follow-up: incidence AD 
decreased during this period 
Rautava et al. [25] 
57 high-risk 
infants for atopy 
Lactobacillus rhamnosus GG  
(2 × 1010 cfu daily) 
R, DB, PC 
Prenatal and 3 months 
postnatally to breastfeeding 
mothers 
Reduction in AD prevalence in 
infants brestfed by mothers in 
probiotic group vs. placebo 
Kopp et al. [26] 
94 high-risk 
infants for atopy 
Lactobacillus rhamnosus GG  
(5 × 109 cfu twice daily) 
R, DB, PC 
4–6 weeks prenatally and  
6 months after delivery 
No reduced incidence of AD and no 
modification of severity 
Kukkonen et al. [27] 
925 high-risk 
infants for atopy 
Lactobacillus rhamnosus GG  
(5 × 109 cfu), L. rhamnosus LC705 
(5 × 109 cfu), Bifidobacterium 
breve Bb99 (2 × 108 cfu), 
Propionibacterium freudenreichii ssp. 
Shermanii JS (2 × 109 cfu)  
twice daily 
R, DB, PC 
From 2–4 weeks prenatally 
to 6 months post delivery 
Probiotics reduced AD 
Dotterud et al. [28] 
292 infants 
without risk 
factor for atopy 
Lactobacillus rhamnosus GG  
(5 × 109 cfu), L. acidophilus La-5 
(5 × 109 cfu), Bifidobacterium 
animalis subsp. lactis  
(5 × 109 cfu) daily 
R, DB, PC 
To non-selected (for atopy) 
mothers from 36 weeks of 
gestation to 3 months 
postnatally (all infants 
breastfed) 
Probiotics reduced the cumulative 
incidence of AD among children at 
2 years of age 
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Table 1. Cont. 
Study Partecipants Probiotics Type of study Duration Outcome 
Huurre et al. [29] 
140 high-risk 
infants for atopy 
Lactobacillus rhamnosus GG  
(1 × 1010 cfu) and Bifidobacterium 
lactis (1 × 1010 cfu) daily 
R, DB, PC 
To mothers from the 1st 
trimester of pregnancy to 
the end of exclusive 
breastfeeding 
Risk of sensitization at 12 months of 
age for infants of atopic mothers, 
was reduced by use of probiotics 
during pregnancy and lactation 
Niers et al. [30] 
102 high-risk 
infants for atopy 
Bifidobacterium 
Bifidum (1 × 109 cfu), 
Bifidobacterium lactis (1 × 109 cfu), 
Lactococcus lactis (1 × 109 cfu) daily 
R, DB, PC 
To mothers from 6 weeks 
prenatally and to infants for 
12 months postnatally  
Probiotics shows a preventive effect 
of incidence of AD in high-risk 
infants during the first 2 years of life 
Kim et al. [31] 
112 high-risk 
infants for atopy 
Bifidobacterium 
Bifidum (1.6 × 109 cfu), 
Bifidobacterium lactis (1.6 × 109 
cfu), Lactobacillus 
Acidophilus (1.6 × 109 cfu) daily 
R, DB, PC 
To mothers from 8 weeks 
prenatally and to 
mothers/infants for  
6 months postnatally 
At 6 and 12 months the prevalence 
of AD in probiotics group was 
reduced than in placebo group. 
Cumulative incidence of AD 
significantly lower in probiotics 
group at 12 months 
Soh et al. [32] 
253 high-risk 
infants for atopy 
Bifidobacterium longum (1 × 107 
cfu), Lactobacillus rhamnosus  
(2 × 107 cfu) daily 
R, DB, PC 
To infants from birth to  
6 months with milk formula
No effect on prevention of AD in 
the first year of life 
Kuitunen et al. [33] 
891 high-risk 
infants for atopy 
Lactobacillus rhamnosus GG  
(5 × 109 cfu), L. rhamnosus LC705 
(5 × 109 cfu), Bifidobacterium 
breve Bb99 (2 × 108 cfu), 
Propionibacterium freudenreichii 
ssp. shermanii JS (2 × 109 cfu) 
twice daily 
R, DB, PC 
To mothers from 36 weeks 
of gestation prenatally and 
to infants postnatally until  
6 months of age 
At 5 years of age no significant 
difference appeared in frequencies 
of AD and IgE associated (atopic) 
eczema between probiotics and 
placebo groups. Only cesarean-
delivered children had significantly 
fewer incidence of AD 
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Table 1. Cont. 
Study Partecipants Probiotics Type of study Duration Outcome 
Wickens et al. [34] 
474 high-risk 
infants for atopy 
L. rhamnosus (6 × 109 cfu) or 
Bifidobacterium animalis subsp. 
lactis (9 × 109 cfu) daily 
R, DB, PC 
To mothers from 35 weeks 
prenatally to 6 months if 
breastfeeding and to infants 
from birth to 2 years 
Only L. rhamnsosus reduced 
cumulative prevalence of AD by  
2 years. No effects for B. animalis 
West et al. [35] 179 infants 
Lactobacillus F19  
(1 × 108 cfu daily) 
R, DB, PC 
To infants during weaning 
from 4 to 13 months of age 
Cumulative incidence of AD at  
13 months of life was lower in 
probiotic group 
Taylor et al. [36] 
178 high-risk 
infants for atopy 
Lactobacillus acidophilus  
(3 × 109 cfu daily) 
R, DB, PC 
Newborn of allergic 
mothers received probiotic 
or placebo for 6 months 
At 6 months or 1 year no reduction 
in AD in probiotic group vs. placebo 
Abrahamsson et al. 
[37] 
188 high-risk 
infants for atopy 
Lactobacillus reuteri ATCC  
(1 × 108 cfu daily) 
R, DB, PC 
Prenatally to mothers from 
36 gestational age and 
postnatally to infants for  
1 year 
For AD similar cumulative 
incidence for probiotic and placebo 
groups. In probiotic group less  
IgE-associated eczema during 2 years 
Boyle et al. [38] 
250 pregnant 
women carrying 
infants at high 
risk of atopy 
Lactobacillus rhamnosus GG  
(1.8 × 1010 cfu) daily 
R, PC 
To pregnant women from 
the 36th week of gestation 
until delivery 
At 1 year of age, no reduction in 
incidence of AD and IgE-associated 
eczema in infants of supplemented 
mothers 
R: randomized; DB: double blind; PC: placebo-controlled. 
Table 2. Probiotics in the treatment of Atopic Dermatitis (AD) in children. 
Study Partecipants Probiotics Type of study Duration Outcome 
Majamaa and 
Isolauri [47] 
27 infants (1st study) 
and 11 breastfed 
infants (2nd study)  
Lactobacillus rhamnosus GG  
(5 × 108 cfu/gm formula or  
2 × 1010 cfu twice daily to 
nursing mothers) 
R, DB, PC 
1st: Cow’s milk elimination 
diet plus formula milk with or 
without LGG for 4 weeks. 
2nd: LGG to mothers during 
breastfeeding for 4 weeks 
After 4 weeks significant 
SCORAD score reduction (extent, 
intensity and subjective score) in 
probiotic group. No difference 
between groups at 2 months 
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Table 2. Cont. 
Study Partecipants Probiotics Type of study Duration Outcome 
Isolauri et al. [48] 
27 infants with AD 
during breastfeeding 
Lactobacillus rhamnosus GG  
(3 × 108 cfu/g) or 
Bifidobacterium lactis  
Bb-12 (1 × 109 cfu/g) 
R, DB, PC 4 weeks 
At 2 months, significant improve 
in SCORAD score in probiotics 
groups 
Kirjavainen et al. 
[49] 
21 infants with early 
onset AD assumed 
hydrolyzed whey 
formula 
Bifidobacterium lactis  
Bb-12 (1 × 109 cfu/g) 
R, DB, PC Not specified 
Probiotic supplementation 
modulates composition of gut 
microbiota and alleviate symptoms 
of atopy 
Kirjavainen et al. 
[50] 
35 infants (5.5 months 
mean age) with AD 
and suspected (CMA) 
Viable Lactobacillus GG  
(1 × 109 cfu/g) or  
heat-inactivated LGG 
R, DB, PC 
Mean length of intervention 
period of 7.5 weeks 
Significant reduction of SCORAD 
score in viable LGG group 
Weston et al. [51] 
53 children  
(6–18 months af age) 
with AD 
Lactobacillus fermentum  
(1 × 109 cfu) twice daily 
R, DB, PC 8 weeks 
Probiotic improved severity of AD 
in children 
Woo et al. [52] 
75 children (2–10 years 
of age) with AEDS 
Lactobacillus sakei (5 × 109 cfu) 
twice daily 
R, DB, PC 12 weeks 
Probiotic supplementation 
improved clinical severity of 
AEDS and decreased chemokine 
levels 
Brouwer  
et al. [53] 
50 children (<5 months 
of age) with AD and 
suspected CMA 
Lactobacillus rhamnosus  
(3 × 108 cfu/g) or Lactobacillus 
GG (3 × 108 cfu/g) 
R, DB, PC 12 weeks 
No clinical or immunological 
effect of probiotics in children 
with AD 
Folster-Holst et 
al. [54] 
54 children  
(1–55 months of age) 
with moderate or 
severe AD 
Lactobacillus rhamnosus strain 
GG (5 × 109 cfu) twice daily 
R, DB, PC 8 weeks 
No significant difference in 
clinical outcome by administration 
of probiotic 
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Table 2. Cont. 
Study Partecipants Probiotics Type of study Duration Outcome 
Gruber et al. [55] 
102 infants  
(3–12 months of age) 
with mild to moderate 
AD  
Lactobacillus rhamnosus strain 
GG (5 × 109 cfu) twice daily 
R, DB, PC 12 weeks 
No therapeutic effect of probiotic 
in mild-to-moderate AD 
Nermes et al. [56] 
37 infants (6.5 months 
mean age) with AD 
Lactobacillus rhamnosus strain 
GG (3 × 157 cfu/g) daily 
R, DB, PC 12 weeks 
SCORAD indices decreased in 
both probiotic and placebo groups 
Gore et al. [57] 
208 children  
(3–6 months of age) 
with AD 
Lactobacillus paracasei  
(1010 cfu) or Bifidobacterium 
lactis (1010 cfu) daily 
R, DB, PC 12 weeks 
No significant difference in 
SCORAD between all groups at 
any time-point up to age 3 year 
Rosenfeldt  
et al. [58] 
43 children with AD  
1–13 years old  
Lactobacillus rhamnosus  
(1010 cfu) and L. reuteri  
(1010 cfu) twice daily 
R, DB, PC 6 weeks 
Moderate improvement of clinical 
severity of AD with administration 
of probiotics Lactobacillus strains 
Rosenfeldt  
et al. [59] 
41 children (mean age 
4 years) with moderate 
and severe atopic 
dermatitis 
Lactobacillus rhamnosus  
(1010 cfu) and L reuteri DSM 
(1010 cfu) twice daily 
R, DB, PC 6 weeks 
Probiotic supplementation may 
stabilize the intestinal barrier 
function with an improvement of 
SCORAD score 
Viljanen  
et al. [60] 
230 children (mean age 
6.4 months) with AD 
and suspected CMA 
LGG (5 × 109 cfu) or mixture: 
LGG (5 × 109 cfu), L. rhamnosus 
LC705 (5 × 109 cfu), 
Bifidobacterium breve  
(2 × 108 cfu), Propionibacterium 
freudenreichii ssp. Shermanii JS 
(2 × 109 cfu) twice daily 
R, DB, PC 4 weeks 
Reduction in SCORAD score only 
in IgE-associated AD in LGG 
group 
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Table 2. Cont. 
Study Partecipants Probiotics Type of study Duration Outcome 
Sistek et al. [61] 
59 children (1–10 years 
of age) with AD 
Lactobacillus rhamnosus  
(2 × 1010 cfu/g) and 
Bifidobacterium lactis  
(2 × 1010 cfu/g) daily 
R, DB, PC 
12 weeks and follow-up until 
18 weeks 
Probiotics improved AD only in 
food sensitized children 
Gerasimov  
et al. [62] 
90 children (1–3 years 
of age) with moderate 
to severe AD 
Lactobacillus acidophilus  
(5 × 109 cfu) and 
Bifidobacterium lactis  
(5 × 109 cfu) twice daily 
R, DB, PC 8 weeks 
Probiotics improved significantly 
clinical severity of AD with a 
greater decrease in SCORAD 
score in children supplemented  
Yeşilova et al. 
[63] 
40 children (1–13 years 
of age) with moderate 
to severe AD 
B. bifidum (2 × 109 cfu),  
L. acidophilus (2 × 109 cfu),  
L. casei (2 × 109 cfu), and  
L. salivarius (2 × 109 cfu)  
twice daily 
R, DB, PC 8 weeks 
Probiotic in AD patients 
effectively reduced the SCORAD 
index 
Passeron  
et al. [64] 
39 children (>2 years 
of age) with moderate 
and severe AD 
Lactobacillus rhamnosus Lcr35 
(1.2 × 109 cfu) plus prebiotic 
preparation vs prebiotic alone 
three times a day 
R, DB 12 weeks 
Both synbiotic and prebiotic alone 
significantly improve the 
manifestations of AD 
Van der Aa et al. 
[65] 
82 infants (0–7 months 
af age) with AD 
exclusively  
formula-fed 
Bifidobacterium breve  
(1.3 × 109 cfu/100 mL) plus 
prebiotic mixture 
R, DB, PC 12 weeks 
Probiotic and prebiotic not have 
beneficial effect on AD severity  
in infants  
Wu et al. [66] 
54 children (2–14 years 
of age) with moderate 
to severe AD 
Lactobacillus salivarius  
(2 × 109 cfu) plus prebiotic vs. 
prebiotic alone 
R, DB 8 weeks 
In probiotic group was seen a 
significantly lower SCORAD 
score at 10 weeks 
R: randomized; DB: double blind; PC: placebo-controlled; CMA :cow’s milk allergy; LGG: Lactobacillus rhamnosus GG. 
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Results from this study showed no significant effect of probiotics on SCORAD score, sensitization, 
inflammatory parameters or cytokine production. In the same year another group of authors [54] 
confirmed the ineffective treatment with respect to clinical symptoms, use of topical corticosteroids 
and antihistamines, immunological parameters or health-related quality of life, of Lactobacillus 
rhamnosus strain GG in 54 infants with moderate to severe AD. In 2007, Gruber et al. [55] performed 
a large trial with 102 infants with mild-to-moderate AD, who were randomized to receive a 
supplementation with Lactobacillus rhamnosus GG or placebo for 12 weeks, finding no therapeutic 
effect. Nermes et al. [56], in a smaller group of atopic infants randomized to receive Lactobacillus 
rhamnosus GG or placebo for 3 months demonstrated the same clinical improvement in SCORAD 
indices in treated and untreated groups. Very recently Gore et al. [57] investigated a dietary 
supplementation of 208 atopic infants with Lactobacillus paracasei or Bifidobacterium lactis for  
12 weeks. Authors showed that probiotics did not provide any additional benefit to topical treatment of 
eczema and they also reported that probiotics did not prevent progression of allergic disease up to age 
3 years. 
The group of Rosenfeldt performed two trials [58,59], in 2003 and 2004, evaluating the effect of a 
mix of Lactobacillus rhamnosus and reuteri in children with moderate to severe AD. In these studies 
patients were randomized to receive placebo followed by active treatment or probiotic strains followed 
by placebo. Results of these trials showed a moderate improvement of clinical severity of eczema in 
children supplemented with mixture of probiotic strains with a more pronounced effect in patients with 
a positive skin prick test; moreover authors demonstrated that probiotic supplementation may stabilize 
intestinal barrier function with clinical benefit for children with AD. In 2005, Viljanen et al. [60] 
randomized 230 infants with AD and suspected cow’s milk allergy receiving Lactobacillus GG, a mix 
of probiotic strains (LGG, L rhamnosus LC705, Bifidobacterium breve, Propionibacterium 
freudenreichii ssp. Shermanii JS) or placebo for 4 weeks. A significant reduction in SCORAD score 
was recorded only in infants with IgE-associated AD in the LGG group, without any other significant 
beneficial effect between the probiotic supplementation vs. placebo. Similar results have been found 
by Sistek et al. [61] in 53 children with AD supplemented for 3 months with a mix of Lactobacillus 
rhamnosus and Bifidobacterium lactis. Results showed a decreasing in severity of AD only in a 
subgroup of children sensitized to food but not in children sensitized to environmental allergens. More 
recently, Gerasimov et al. [62] evaluated a 8-week supplementation of a mixture of Lactobacillus 
acidophilus and Bifidobacterium lactis in 90 children with moderate to severe AD, demonstrating a 
significant improvement in clinical severity in treated patients. Another recently published trial by 
Yeşilova et al. [63] evaluated a probiotic mix of Bifidobacterium bifidum, Lactobacillus acidophilus, 
Lactobacillus casei, and Lactobacillus salivarius in 40 children with moderate to severe AD. The  
8-week intervention significantly reduced the SCORAD index in the treated children respect to 
placebo group. Moreover, probiotics supplementation significantly reduced the serum cytokines IL-5, 
IL-6, IFN-γ and total serum IgE levels. 
Three other published studies were performed to evaluate the effect of probiotic strains in 
association with a prebiotic preparation. Passeron et al. [64] randomized 39 children with moderate to 
severe AD to assume Lactobacillus rhamnosus Lcr35 plus a prebiotic or an identical appearing 
prebiotic preparation, finding that a synbiotic treatment was not superior to prebiotic alone. Analogous 
results were found by van der Aa et al. [65] in 2010: a synbiotic mixture (Bifidobacterium breve plus 
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galacto-fructo-oligosaccharide) or placebo were randomly administered to 82 infants with AD. 
Authors concluded that synbiotic mixture does not have a beneficial effect on AD severity. On the 
contrary, very recently, Wu et al. [66] compared the effects of Lactobacillus salivarius plus  
fructo-oligosaccharide or prebiotic alone for 8 weeks on 54 children with moderate to severe AD.  
At 10 weeks, results of this trial showed a superior role of synbiotic combination for treating AD. 
Despite the amount of data, reviews, meta-analysis and a Cochrane Collaboration review published 
in last 4 years do not definitively clarify the role of probiotics in treatment of PAD. The majority of 
these reviews [40,42,43,67,68] and the Cochrane Collaboration review [69] concluded that there is not 
enough evidence to support a recommendation for the use of probiotics for treatment of AD in 
children. Only Michail et al. [70] reported data from a meta-anlysis suggesting that there is a modest 
role for probiotics in treatment of moderately severe pediatric AD. 
5. Conclusions 
Analyzing data from the randomized controlled studies evaluated in this review, we can observe 
that a single strain of probiotic administration was studied more than mixtures of strains. Although we 
noted that studies performed with a mixture of probiotic strains show to be slightly more efficacious 
than single strain studies, there is currently insufficient evidence to suggest a mixture probiotic strains 
rather than a single strain supplementation. This hypothesis is in accordance with other authors [60] 
suggesting that a mixture of probiotic strains may be no better than a single probiotic. According to the 
literature, the most studied strains were Lactobacilli (especially LGG) and Bifidobacteria (especially 
Bb12), and the first one, both when used in single administration or in a mixture of strains, seems to be 
the most effective. Nevertheless, regardless of specific probiotic strain, a dose less than of 109 cfu/day 
should not be administered. 
However, taken together results are conflicting. The vast heterogeneity in study design, regarding 
for example the characterization of patients (number, age, severity of disease, sensitization to 
allergens, presence of other allergic diseases), dosage of probiotics, duration of supplementation, use 
of a single strain or a mixture and length of follow-up are possible explanations. Moreover, trials are 
complicated by natural tendency of AD to improve over time. So, before a recommendation to perform 
further large, well-designed randomized controlled trials may be done, clear guidelines to delineate the 
use of probiotic strains in clinical trials are needed. In 2010, a group of authors [71] proposed these 
guidelines in a review for study design, target populations, selection of placebo and probiotic 
microorganism(s), duration of follow-up, outcome and endpoint measurements, safety assessments and 
regulatory considerations. So, only with a significant reduction in heterogeneity of studies, results from 
future trials will be useful for patients. 
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